USA flag logo/image

An Official Website of the United States Government

siRNA Modulation of the Immune Response

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43AI100398
Solicitation Year:
2013
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-123
Small Business Information
VIROGENICS, INC.
PO BOX 2702 DEL MAR, CA 92014-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: siRNA Modulation of the Immune Response
Agency: HHS
Contract: 1R43AI100398-01A1
Award Amount: $600,000.00
 

Abstract:

DESCRIPTION (provided by applicant): A major goal expressed by NIAID and other agencies charged with development of the U.S. biodefense research strategy is a broad spectrum activity that mitigates catastrophic biothreats across a wide spectrum of agents.Such therapeutic activities have been difficult to identify and require new understanding and paradigms of the immune system or the pathogens. The novel discovery that reduced expression of CD45, a protein associated with immune cells, profoundly modulates the immune response capability in a manner that protects the host against a variety of lethal pathogens provides opportunities for novel therapeutic interventions that target the host immune system to achieve the goal of a broad spectrum activity. The approach is based on findings using a series of mice genetically modified to express reduced levels of CD45. Reduced CD45 expression was shown to provide survival protection from three Category A (B. anthracis, Ebola virus and Marburg virus) and one Category C (influenza) biodefense pathogens. Since these four pathogens represent highly diverse infectious organisms and pathologies, it is likely that the reduction of CD45 will also provide therapeutic benefit against additional pathogens. Thus, the significance of the proposed studies is not only the potential for pathogen protection from a biodefense standpoint but also for pandemic disease control. The reduction of CD45 expression to enhance immune protection against biodefense pathogens represents anew and unexpected property of CD45 and a novel approach for immunotherapy. Since permanent, genetically-reduced CD45 expression, as occurs when only one functional gene copy is present, produces no detectable adverse effects in mouse or human, a therapeutic that induces transient reduction of CD45 function is very likely to have an excellent safety profile, particularly if only CD45 is targeted. One approach to such selective targeting is to utilze CD45-specific genetic sequences. CD45-specific siRNA willbe delivered using a unique lipid-polymer hybrid nanoparticle platform to achieve selective CD45 reduction. This feasibility study will test and advance this technology, initially using cultured cells followed by evaluation of CD45 reduction and modulationof immune function in mice. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Reduction of CD45 expression protects against lethal infections from diverse bacterial and viral pathogens providing opportunities for a broad spectrum therapeutic. The ultimate goal of this project is to inhibit CD45 production with small interfering RNA (siRNA) to a level that provides survival benefit to a variety of biothreats. Advanced nanoparticle technology will be used to deliver the siRNA to the appropriate cells.

Principal Investigator:

William C. Raschke
858-775-0453
braschke@virogenicsinc.com

Business Contact:

William C. Raschke
858-450-2561
braschke@virogenicsinc.com
Small Business Information at Submission:

VIROGENICS, INC.
PO BOX 2702 DEL MAR, CA 92014-

EIN/Tax ID: 142157802
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No